FDA Approves GSK's Hibsago, a Hepatitis B Drug That May Let Some Patients Stop Long-Term Treatment
In two trials, 19% of patients given the injection kept the virus under control 24 weeks after stopping all hepatitis B treatment. The drug carries a boxed warning for serious liver reactions and low platelet counts.
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources
Brief
The Food and Drug Administration on Tuesday, Oct. 20, approved GSK's Hibsago, or bepirovirsen, an injection given with…
More reporting and context continue here.
The complete story is available with Premium.
Read the facts, open questions and supporting sources.
Continue reading with NewsPlain Premium.
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.